Advances in Medicine — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$8,467	4
2020	Research	$108,471	9
2019	Research	$248,248	21

Breakdown

Who paid Research payments · program years 2019–2021

AstraZeneca Pharmaceuticals LP $342,437 22 payments
Genentech, Inc. $22,508 8 payments
Pfizer Inc. $144 3 payments
Novartis Pharmaceuticals Corporation $96 1 payment

Studies the money was for Research payments · program years 2019–2021

A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector with Home-administered Tezepelumab in Adolescent and Adult Subjects with Severe Asthma $155,191 4 payments
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $65,288 4 payments
A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $60,674 6 payments
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. $38,486 6 payments
PH Iib of Mstt1041a in Severe Uncontrolled Asthma $22,508 8 payments
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $21,548 1 payment
Double blind Randomized Placebo controlled Parallel group Study to Evaluate the Effect of Aclidinium Bromide on Long Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD $1,250 1 payment
A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $144 3 payments
A Randomized Double Blind Double Dummy Placebo Controlled Parallel Group Study to Assess the Efficacy and Safety of Different Doses of Indacaterol in Adult Patients With Persistent Asthma Using Salmeterol As An Active Control $96 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.